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Antiarrhythmic therapy in 506 consecutive patients under-
going 1,268 antiarrhythmic drug trials for ventricular
tachycardia or ventricular fibrillation was reviewed for
evidence of arrhythmogenic drug effect defined as the
occurrence of a new form of ventricular tachyarrhythmia
temporally associated with initiation of drug therapy or
dosage increase. Arrhythmogenic effects occurred in 6 . %
of patients and 3 .4% of drug trials . This ranged from a
high of 11 .8% caused by encainide to none occurring with
procainamide, tocainide or beta-adrenergic blocking drugs .
The incidence of arrhythmogenesis was significantly greater
in patients whose presenting arrhythmia was sustained
ventricular tachycardia than it was in those who presented
with nonsustained ventricular tachycardia or ventricular
fibrillation (p = 0 .02) .
Since its introduction into clinical practice, quinidine has
been noted to be associated with syncope and sudden death
due to ventricular tachyarrhythmias (1,2) . In recent years,
arrhythmogenic actions have been attributed to virtually all
antiarrhythmic drugs . However, most reports either have
been anecdotal or have focused on the arrhythmogenic
potential of a single drug or a specific arrhythmia . Velebit et
al. (3) determined the overall incidence of arrhythmogenic
effects of antiarrhythmic therapy in a large series of patients
treated for ventricular arrhythmia during a protocol of
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Decreased systolic function measured echocardiograph-
ically at the base of the left ventricle was associated with an
increased incidence of arrhythmogenic effects (p = 0 .006)
whereas global left ventricular ejection fraction was not .
Age, gender, cardiac diagnosis, location of prior myocar-
dial infarction and New York Heart Association functional
class for heart failure were not related to the occurrence of
drug-induced arrhythmias . These findings emphasize the
need for in-hospital cardiac monitoring during initiation of
antiarrhythmic drug therapy for ventricular tachyarrhyth-
mias .
(J Am Coll Cardiol 1 8  ;14
 20 -15)
20 
short-term drug testing. No other study has been published
on the frequency of arrhythmogenic effects of a variety of
antiarrhythmic drugs used in a large population of patients .
In the present study, arrhythmogenic drug effects were
defined as the new occurrence of ventricular fibrillation or of
a form of ventricular tachycardia not previously experienced
by that patient . The purpose of the study was to define the
incidence of these arrhythmogenic drug effects in a large
patient group treated for recurrent ventricular tachycardia or
ventricular fibrillation and to analyze the association of these
effects with clinical variables that might predict their occur-
rence .
Methods
Study group (Table 1) . The study group consisted of 506
consecutive patients (388 men and 118 women aged 13 to 88
years [mean 56 ± 13]) evaluated and treated for recurrent
ventricular tachycardia or ventricular fibrillation at Indiana
University Medical Center . Before therapy, 184 patients had
sustained ventricular tachycardia, 130 had ventricular fibril-
0735-10 7/8 /$3 .50
lation and 1 2 had nonsustained ventricular tachycardia .
Primary electrical disease was defined as the absence of
structural heart disease on clinical examination, echocar-
diography and catheterization . Endomyocardial biopsy was
not systematically performed in this subgroup . Patients with
Wolff Parkinson-White syndrome were included if they had
documented ventricular tachycardia or ventricular fibrilla-
tion that was not associated with atrioventricular reciprocat-
ing tachycardia or atrial fibrillation with a rapid ventricular
response .
Left ventricular function . Three hundred thirty-eight pa-
tients had baseline assessments of left ventricular size and
function. Left ventricular (LV) ejection fraction was deter-
mined by contrast or radionuclide ventriculography or two-
dimensional echocardiography . Echocardiograms were fur-
ther analyzed to derive the fractional shortening, which was
calculated as the ratio of systolic change in left ventric-
ular internal diameter (LVID) to the diastolic diameter  
(LVIDdiastole - LVIDsystoie)/LVID
diastole .
Fractional area
change was similarly calculated from the measurements
at the mid-ventricular level as (LV aread ;astole - LV
areasystoie)/LV areadiastole .
Antiarrhythmic drug treatment . Each patient was hospi-
talized and the cardiac rhythm was continuously monitored
during a drug-free period of >2 days and during administra-
tion of all antiarrhythmic drugs . Twenty-four hour monitor-
ing of the patients' cardiac rhythm was accomplished by
telemetry with use of a commercially available computerized
arrhythmia detection system (Hewlett-Packard 78525) and
was continuously observed by experienced cardiac intensive
care unit nurses . Rhythm tracings were reviewed daily by
physicians . The choice of specific antiarrhythmic drugs was
individualized and based on each patient's previous drug
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history and clinical state and the availability of specific
drugs . A previously administered drug was not reevaluated if
limiting side effects or recurrent arrhythmia had occurred
during prior exposure to that agent . Drugs with significant
negative inotropic effects, such as disopyramide or beta-
adrenergic blocking agents, were not administered to pa-
tients who had overt congestive heart failure . Drugs that
were investigational when the patient entered the study were
tested after drugs approved by the Food and Drug Admin-
istration were evaluated . Each drug, except for amiodarone,
which was given for 7 to 14 days, was administered for 2 to
4 days at each dose and, if discontinued because of adverse
effects or lack of efficacy, administration of another drug was
not begun for at least another 24 h . If single drug therapy
appeared ineffective, drug combinations were employed
using the same guidelines as for single drugs . Each drug
combination was evaluated as a separate, unique drug trial
and was not included in the individual analysis of single
drugs . The most frequent combinations involved amio-
darone, which was paired with quinidine in 20 trials, encain-
ide in 13, aprindine in 13 and mexiletine in 12 .
Definition of arrhythmogenic effects . An arrhythmogenic
effect of antiarrhythmic drug therapy was defined as the
spontaneous occurrence of a new symptomatic ventricular
tachyarrhythmia that occurred in temporal association with
the start of drug administration or a new increase in dosage
and that abated once administration of the drug was discon-
tinued. Drug-induced arrhythmias were analyzed solely on
the basis of spontaneous arrhythmias observed during elec-
trocardiographic (ECG) monitoring. Whereas electrophysio-
logic testing was employed to evaluate drug efficacy, these
data were not used to define arrhythmogenic drug effects .
Arrhythmogenic effects were categorized further into   1)
repetitive nonsustained ventricular tachycardia, defined as
recurrent salvos (usually of 3 to 10 complexes) of ventricular
tachycardia separated by brief periods of sinus rhythm ; 2)
sustained ventricular tachycardia, defined as ventricular
tachycardia lasting >30 s or requiring termination because of
hemodynamic compromise ; 3) incessant ventricular tachy-
cardia, defined as continuous ventricular tachycardia that
could not be terminated by electrical cardioversion or pacing
or that recurred immediately after termination ; 4) polymor-
phic ventricular tachycardia ; 5) ventricular fibrillation,
which was primary (that is, was not a result of degeneration
of ventricular tachycardia) . To be noted as an arrhyth-
mogenic response, the arrhythmia had to be new for that
patient . Therefore, patients who had sustained ventricular
tachycardia or ventricular fibrillation as their primary ar-
rhythmia would not be included as having an arrhyth-
mogenic event if that same arrhythmia occurred during drug
therapy . Likewise, a change in the rate or configuration of
sustained or nonsustained ventricular tachycardia during
arrhythmia recurrence was not considered as an arrhyth-
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Table 1 . Clinical Characteristics of 506 Study Patients
n
Clinical arrhythmia
Nonsustained ventricular tachycardia 1 2
Sustained ventricular tachycardia 184
Ventricular fibrillation 130
Cardiac diagnosis
Ischemic heart disease
308
Anterior infarction   
Inferior infarction
103
Anterior + inferior infarction 25
Non-Q wave infarction 16
No infarction
65
Dilated cardiomyopathy 6 
Primary electrical disease
6 
Mitral valve prolapse 30
Other valvular heart disease 14
Wolff-Parkinson-White syndrome
7
Congenital heart disease 5
Hypertensive heart disease
4
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Table 2 . Antiarrhythmic Drug Doses and Number of Study Trials
mogenic response if the sustained or nonsustained ventricu-
lar tachycardia occurred before drug treatment .
Electrocardiographic intervals . QRS, QT and corrected
QT (QTc) intervals were obtained in the control state before
antiarrhythmic drug therapy and on the day of the arrhyth-
mogenic event. These intervals were compared with those
obtained from a subgroup of patients from our study group
not experiencing an arrhythmogenic event . This latter sub-
group was matched to the former one with respect to age,
gender, left ventricular size and function and antiarrhythmic
drug. For analysis, patients experiencing arrhythmogenesis
while receiving amiodarone were compared with those hav-
ing an uneventful amiodarone drug trial . Likewise, patients
receiving flecainide, encainide or propafenone were grouped
together to compare those with and without arrhythmogenic
drug effects . The number of patients having arrhythmogen-
esis while receiving other drugs was too small to perform
meaningful analysis .
QT intervals were measured from the onset of the QRS
complex to the termination ofthe T wave . The QTc intervals
were calculated as QT/VRR. JT intervals were calculated as
QT -' ~QRS . JTc intervals were calculated as (QT -
QRS)/ V RR.
Statistical analysis . Data are presented as mean values
I SD. Comparisons between patients who did or did not
experience arrhythmogenic effects were made with use of
the Student's t test for continuous variables such as frac-
tional shortening . Categorical variables, such as presenting
arrhythmia, were analyzed by the chi-square test for contin-
gency tables. Electrocardiographic intervals were analyzed
by two-way repeated measures analysis of variance . Statis-
tical significance was assigned to probability values <_0 .05 .
Results
Incidence of arrhythmogenesis (Table 2). Arrhythmogenic
drug effects were identified in 35 (6. %) of 506 patients and
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Figure 1 . Incidence of arrhythmogenic effects for each drug . The
numbers to the right of the bars represent the number of arrhyth-
mogenic drug trials per total number of trials for that drug .
in 43 (3 .4%) of 1,268 drug trials (Fig . 1). Each of the 35
patients who experienced an arrhythmogenic effect while
receiving one drug received at least one additional drug trial .
Four patients had arrhythmogenic responses during more
than one drug trial (two patients had two arrhythmogenic
drug responses and one each had three and five such
responses) . Encainide produced the highest incidence rate
(11 .8%) of arrhythmogenic effects, and this incidence rate
was statistically greater than that for all other drugs com-
bined by the chi-square test (p < 0 .001) . Of the 13 drug trials
with encainide . 4 were in patients treated during early
investigational trials that used an incremental dosing regi-
men that exceeded the current recommendations for dose
escalation . The incidences of arrhythmogenesis varied
among the remaining drugs, but these differences did not
attain statistical significance . Drug combinations produced
arrhythmogenic responses in four trials . A combination of
amiodarone and flecainide was arrhythmogenic in two of the
three trials in which it was used whereas amiodarone plus
propafenone had arrhythmogenic effects in one of nine trials
and amiodarone plus quinidine in one of 20 trials .
Type of arrhythmogenic effect. The specific categories of
arrhythmogenic responses for each drug are presented in
Figure 2 . Incessant ventricular tachycardia accounted for 23
of the 43 drug-induced arrhythmias . Polymorphic ventricular
tachycardia and ventricular fibrillation occurred in six in-
stances and were only associated with amiodarone therapy
in this series .
Arrhythmogenic effects occurred at a mean of 4 .  ± 3 .8
days (median 3 ; range I to 17) after drug initiation . For all
drug trials, therapy during continuous ECG monitoring
211
Drug
Dose
(mg/day)
Number of
Trials
Amiodarone 800 to 1,600 load 256
Quinidine 1,200 to 1,600 167
Propafenone 450 to  00 162
Encainide 75 to 300 110
Disopyramide 400 to 600  5
Aprindine 75 to 200 88
Mexiletine 450 to  00 7 
Procainamide 2,000 to 6 .000 77
Beta-blockers - 43
Tocainide 1,200 to 1,800 2 
Flecainide 100 to 400 25
Cibenzoline 1 5 to 2 3 23
Combinations - 114
ENCAINIDE
13/110
CIBENZOLINE 2/23/!!!!!!!!!!!!!/~!/!!!
.!
PRO PA FEN ONE
8/162
FLECAINIDE 1/25
AMIODARONE
10/256%!/Z!Z/Z/i
APRINDINE
/!!/Zo 2/88
MEXILETINE /!/ 1/7 
DISOPYRAMIDE
i!/
.
1/ 5
QUINIDINE 1/167
PROCAINAMIDE 0/77
BETA BLOCKERS
0/43
TOCAINIDE
0/2 
COMBINATIONS 4/114
%!!/!!!!i
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Figure 2. Type of arrhythmogenic response seen for each drug .
Amio = amiodarone; Comb = combination therapy ; Eric = encain-
ide ; Flec = flecainide ; Propf = propafenone   Quin = quinidine   VF
= ventricular fibrillation   VT-NS and VT-S = nonsustained and
sustained ventricular tachycardia, respectively .
lasted a mean of 6
.6 ± 6 .5
days and ranged from a mean of
4.7 ± 2 .8 days for trials of disopyramide to a mean of 11 .7
6 .1 days for trials of amiodarone . Arrhythmias associated
with amiodarone treatment occurred 3 to 17 days after drug
initiation and resolved within 24 h, except in two patients in
whom incessant ventricular tachycardia lasted for 2.5 and 3
days, respectively ; the latter patient was receiving amio-
darone in combination with flecainide .
Treatment . Therapy consisted of discontinuing the of-
fending drugs and administering intravenous antiarrhythmic
agents or electric cardioversion as indicated . Four patients
required extraordinary treatment . Two of these patients
required vasopressor drugs, one of whom additionally had
placement of an intraaortic balloon pump . Another patient
required prolonged cardiopulmonary resuscitation inter-
mittently for 6 h . The fourth patient died as a result
of cardiogenic shock related to incessant ventricular
tachycardia.
Table 3. Comparison of Variables of Left Ventricular Size and Function Between Patients With
and Without Arrhythmogenic Effects
*p = 0.006 for fractional shortening of patients with arrhythmogenic effects versus those
w ithout . LV = left
ventricle .
10.3%*
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Figure 3 . Incidence of arrhythmogenic effects as related to present-
ing arrhythmia . Abbreviations as in Figure 2
.
Factors associated with arrhythmogenesis . Clinical and
demographic factors were compared between the 35 patients
with and the 471 patients without arrhythmogenic drug
effects. Age, gender, cardiac diagnosis, location of prior
infarction and functional class were not different between
the two groups . Serum potassium concentrations in 20
patients at the time of the drug-induced arrhythmia ranged
from
3.5 to
5 .4 mEq/dl (mean
4
.2 ± 0.5) .
Digitalis was being
used concurrently in 14 of
35 patients and in 14 of 43 drug
trials with arrhythmia exacerbation .
The nature of the presenting arrhythmia
appeared to
influence the likelihood of a patient experiencing an arrhyth-
mogenic effect during drug therapy . Arrhythmogenic effects
occurred in 1  (10.3%) of 184 patients presenting with
sustained ventricular tachycardia, compared with only 3
(2.3%) of 130 patients with ventricular fibrillation and 13
(6.8%) of 1 2 patients with nonsustained ventricular tachy-
cardia (p = 0.02) (Fig . 3) .
Echocardiographic and ventriculographic data concern-
ing left ventricular function and ejection fraction are pre-
2 5 1 1
 
3 1 1 5
8 3
2 4 6 23
2 2
4 4
Arrhythmogenic
Effects
In = 231
No Arrhythmogenic
Effects
In = 280)
Normal
Range
LV diameter (cm)
Diastole 5 .7 ± 0 .2 5 .4 ± 0 .1 3 .6 to 5
.2
Systole 4.5
± 0 .2 4 .2 ± 0 .1 2 .3 to 3 . 
Fractional shortening 0 .16 ± 0 .02* 022±0.01 0 .18to0 .42
LV area (cm'- )
Diastole
24 .5 ± 2 .1 242±0.7
  .5 to 22 .3
Systole 16 .7 ± 1 .  16 .3 ± 0 .7
4 .0 to 11 .6
Fractional area change
0 .36 ± 0 .03 0 .35 ± 0 .01 0 .36 to 0 .64
LV ejection fraction (%) 37 .  ± 3 .2 (n=25) 38 .2 ± 1 .8 (n= 1)
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Table 4 . Left Ventricular Size and Function in Patients Receiving Flecainide, Disopyramide or
Beta-Blockers (F, D, BB) and in Patients Receiving Other Drugs .
Data are given as mean values ± SE . n - number of patients having that measurement . Abbreviations as Table 3 .
sented in Table 3 . The mean value for echocardiographic
fractional shortening, an index of systolic ventricular wall
motion at the base of the heart, was abnormal for patients
who had arrhythmogenic effects and was significantly less
than that obtained in patients without drug-induced arrhyth-
mias (0.16 ± 0.02 versus 0.22 ± 0.01, p = 0 .006) . Other
measurements of left ventricular chamber size and ejection
fraction were not significantly different between the two
groups. A further analysis by specific drug revealed that
echocardiographic measurements of left ventricular size and
systolic function were significantly better in those patients
who were given trials of flecainide, disopyramide and beta-
adrenergic blocking agents than in patients who did not
receive these drugs (Table 4) .
Electrocardiographic intervals . There were no differences
between those patients experiencing arrhythmogenic events
and the matched subgroup in those receiving amiodarone
with regard to the QRS, QT or QTc intervals in the control
period or during treatment with the drug. The groups receiv-
ing flecainide, encainide or propafenone showed no differ-
ences in QT, QTc, JT . JTc or control QRS . However, the
group not experiencing an arrhythmogenic effect had a
greater drug-induced QRS lengthening (124 ± 26 versus
108 ± 21 ms   p = 0.004) .
Discussion
Definition . The definition of arrhythmia exacerbation in
this study was based entirely on the clinical observation and
recording of a new form of ventricular tachyarrhythmia that
occurred during drug therapy and disappeared after drug
discontinuation . It is unlikely that these arrhythmias repre-
sented the natural evolution of the clinical arrhythmia pat-
tern of each patient because, in each patient, the arrhythmia
designated as drug-induced had not been noted previously
and resolved after the drug was discontinued except in one
patient who died with incessant ventricular tachycardia .
Furthermore, a treatment regimen was eventually found that
prevented the clinical arrhythmia and was not associated
STANTON ET AL
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with the previously noted drug-associated arrhythmia . A
more certain diagnosis might have been possible if the
patients had been rechallenged with each potentially ar-
rhythmogenic drug, but this procedure was neither practical
nor safe in the present context. Limiting the designation of
arrhythmogenic effects to the time period of in-hospital
continuous ECG monitoring and to the stated arrhythmia
categories was designed to provide more certainty to the
diagnosis . The occurrence of an arrhythmia later in drug
therapy would more likely reflect progression of disease or
result from other precipitating factors . The definition of
arrhythmogenic effects in this study was derived so as to
avoid the natural variability in extrasystole frequency (4)
that can simulate antiarrhythmic (5) or arrhythmogenic (6)
effects .
Other studies . Velebit et al . (3) reported an overall inci-
dence of drug-associated arrhythmias greater than that in the
present series . Whereas the study groups were largely com-
parable, these authors used short-term drug testing and
identified arrhythmogenic effects as an increase in the fre-
quency of ventricular extrasystoles or the occurrence of
ventricular tachycardia as compared with control period
monitoring of up to 48 h . In the present study, only new
forms of ventricular tachycardia or ventricular fibrillation
not previously present in that patient were designated as
drug-induced . In addition, our study has added an analysis of
the arrhythmogenic potential of several newer drugs such as
encainide, flecainide and amiodarone . Previous reports (7- )
of the arrhythmogenic potential of either encainide or
flecainide agree with our findings . Whereas 4 of the 13
instances of arrhythmia aggravation with encainide in our
series may have been related to rapid dose increases, current
guidelines, which were followed in the other nine cases, did
not obviate the arrhythmogenic potential of encainide . Sim-
ilar results have been noted with flecainide, with a much
higher arrhythmogenic potential reported in patients treated
for sustained ventricular tachyarrhythmias ( ) .
Several reports (10-12) have identified the potential of
amiodarone,
during the early phase of drug loading, to
Variable F.D . BB (n) Other (n) p Value
LV diameter (cm)
Diastole 5 .1 ± 0.1 (111) 5 .6 ± 1 )1 2) <0 .001
Systole 3 .8 ± 0.1 (10 ) 4 .5 ± 0 .1 (16 ) <0
.001
Fractional shortening 0 .25 ± 0.01 (108) 0 .1  ± 0 .01 (16 ) <0 .001
LV Area (cm')
Diastole 21 .5 ± 0.  (88) 25 .8 ± 0 .  (145) 0 .002
Systole 13 .0 ± 0.8 (8 ) 18 .5 ± 0 .  (144) 0 .001
Fractional area change 0 .42
± 0 .01 (88)
0 .31 ± 0 .01 (144) 0 .001
LV ejection fraction (%) 44 ± 4 (32) 36 ± 2 (84) 0 .045
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produce polymorphic ventricular tachycardia, ventricular
flutter or ventricular fibrillation . The reported incidence
rates of arrhythmia aggravation with amiodarone have
ranged as high as 3. % (13), which is the same as that in our
report .
Drug combinations . Drug combinations are usually em-
ployed to obtain added antiarrhythmic efficacy but also have
the risk of enhancing potential toxicity . Because in our
experience combination drug therapy has usually involved
amiodarone as one of the agents, it is not surprising that all
four cases of arrhythmia aggravation we reported involved
amiodarone in combination with another drug . The potential
danger of drug combinations with amiodarone has been
reported by others (14,15) . The noted pharmacokinetic in-
teractions between amiodarone and other antiarrhythmic
drugs may be a contributing factor (14,16) . However, in our
series, careful dose adjustments and plasma concentration
monitoring did not prevent this complication .
Clinical correlates . Of the clinical variables assessed, the
presenting arrhythmia and left ventricular function at the
base of the heart were statistically associated with the
occurrence of drug-induced arrhythmia. As noted by others
(17,18), patients who presented with sustained ventricular
tachycardia more commonly experienced arrhythmogenic
effects than did those who had ventricular fibrillation or
nonsustained ventricular tachycardia . However, these latter
diagnoses did not imply that drug therapy was safe-they
accounted for nearly half of the episodes of potentially
life-threatening drug-induced arrhythmia . Left ventricular
ejection fraction did not distinguish between the patient
groups perhaps because a large majority of patients in the
study had significantly impaired left ventricular function .
There was a small but significant difference between groups
in systolic function at the base of the heart, measured as
fractional shortening by echocardiography . This measure-
ment has been found to be useful in other clinical settings
(1 ), but the mechanism for this relation is not known .
The finding that both groups of patients receiving type IC
agents (flecainide, encainide, propafenone) had lengthening
of the QRS interval but that the magnitude of effect was
greater in those not having an arrhythmogenic event was
surprising and cannot be readily explained .
Arrhythmogenesis occurred early during treatment in this
study . This finding agrees with the data of Minardo et al .
(20), who studied a separate group of patients referred to our
institution after they experienced ventricular fibrillation as
outpatients while receiving antiarrhythmic drugs. The me-
dian duration of drug therapy before ventricular fibrillation
in that group was 4 days compared with 3 days in our current
report.
Limitations . In our study the choice of specific drug
therapy was influenced by each patient's hemodynamic
status, but this precaution did not preclude completely the
arrhythmogenic potential of these drugs . We did not system-
atically record plasma drug concentrations because they
were unavailable for certain investigational drugs (e .g .,
propafenone and aprindine) and because the correlation
between drug concentration and electrophysiologic effect is
unknown in others (e .g ., amiodarone and encainide) . Fur-
thermore, plasma drug concentrations have been shown not
to correlate with arrhythmogenesis (2,12,18) .
Conclusions. Potentially life-threatening arrhythmias in-
duced by antiarrhythmic drugs were found in 6. % of
patients and 3 .4% of drug trials in this group of patients
treated for ventricular tachycardia and ventricular fibrilla-
tion . The incidence varied with the drug employed, and
although there was an association with sustained ventricular
tachycardia as the presenting clinical arrhythmia and re-
duced left ventricular systolic function at the base of the
heart, the occurrence of arrhythmogenic drug effects was
generally unpredictable . Moreover, these effects occurred
despite careful attention to correction of underlying heart
failure and electrolyte imbalance and careful individual drug
selection . These data should argue strongly for careful
in-hospital arrhythmia surveillance to detect and treat a
potentially fatal but reversible complication of antiarrhyth-
mic drug therapy in this patient group .
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